Does vitamin D improve markers of vascular health in type 2 diabetes?

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2005-003615-70-GB

Enrollment

Registered

2005-08-25

Start date

2005-09-26

Completion date

Unknown

Last updated

2017-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus

Interventions

Trade Name: Ergocalciferol Product Name: Ergocalciferol Pharmaceutical Form: Capsule* Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Age >= 18 yrs Vitamin D level of =65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Serum creatinine > 200 umol/L Liver function tests >3 x upper limit of normal Corrected calcium >2.55 mmol/L or <2.15 mmol/L Metastatic malignancy Inability to give informed consent

Design outcomes

Primary

Measure	Time frame
Main Objective: To ascertain whether vitamin D improves endothelial function in type 2 diabetes, as measured by flow-mediated dilatation of the brachial artery;Secondary Objective: To ascertain whether vitamin D reduces pulse wave velocity, improves insulin sensitivity and alters renin-angiotensin system parameters in type 2 diabetics;Primary end point(s): Last visit of patient	—

Countries

United Kingdom

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026